Skip to content

Oxycodone

FDA-approved product (capsule, extended release, oral), marketed as Xtampza Er, Oxaydo, Oxycodone Hydrochloride and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Oxycodone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic pain
  • Drug dependence
  • Pain
  • Substance abuse

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Natural opium alkaloids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA42.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae44.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Oxycodone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery

    NCT00679614 · start 2007-12-17

    Registered record
    Registry ID
    NCT00679614
    Conditions
    Hip Arthroplasty; Knee Arthroplasty; Spinal Anesthesia
    Interventions
    tramacet, naloxone; tramacet; Acetaminophen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-12-17
    Completion
    2011-05-31
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHip Arthroplasty; Knee Arthroplasty; Spinal Anesthesia
    Interventiontramacet, naloxone; tramacet; Acetaminophen
    PhasePhase 3
    Registry statusCompleted
  • The Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache

    NCT00574015 · start 2007-12

    Registered record
    Registry ID
    NCT00574015
    Conditions
    Toothache
    Interventions
    hydrocodone/acetaminophen; bupivacaine (supraperiosteal nerve block)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-12
    Completion
    2013-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionToothache
    Interventionhydrocodone/acetaminophen; bupivacaine (supraperiosteal nerve block)
    PhasePhase 4
    Registry statusCompleted
  • Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy

    NCT00654069 · start 2007-09

    Registered record
    Registry ID
    NCT00654069
    Conditions
    Pain
    Interventions
    Placebo; Acurox 5/30 mg; Acurox 7.5/30
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-09
    Completion
    2008-03
    Enrolment
    405

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain
    InterventionPlacebo; Acurox 5/30 mg; Acurox 7.5/30
    PhasePhase 3
    Registry statusCompleted
  • A Study to Determine the Fasting Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

    NCT01100086 · start 2007-01

    Registered record
    Registry ID
    NCT01100086
    Conditions
    Healthy Volunteers
    Interventions
    Reformulated OXY (oxycodone HCl); Original OxyContin® (OXY) (oxycodone HCl)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2007-01
    Completion
    2007-06
    Enrolment
    84

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionReformulated OXY (oxycodone HCl); Original OxyContin® (OXY) (oxycodone HCl)
    PhasePhase 1
    Registry statusCompleted
  • Opioid and Cannabinoid Pharmacokinetic Interactions

    NCT00308555 · start 2006-05

    Registered record
    Registry ID
    NCT00308555
    Conditions
    Pain
    Interventions
    Cannabis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-05
    Completion
    2009-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain
    InterventionCannabis
    PhasePhase 1
    Registry statusCompleted